Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical
stage biopharmaceutical company developing therapeutic products for rare
disorders, today announced the pricing of its previously announced
underwritten public offering of common stock consisting of 2,150,000
shares at $47.53 per share. In connection with this offering, Synageva
granted to the underwriters a 30-day option to purchase 322,500
additional shares of common stock.
Morgan Stanley and J.P. Morgan are acting as joint book-running managers
in the offering, and Cowen and Company, Canaccord Genuity Inc., and
Leerink Swann LLC are acting as co-managers in the offering.
The securities described above are being offered by Synageva pursuant to
a Form S-3 shelf registration statement (including a base prospectus)
previously filed the Securities and Exchange Commission ("SEC"). Before
you invest, you should read the prospectus in the registration statement
and related prospectus supplement that Synageva has filed with the SEC
for more complete information about Synageva and this offering. The
prospectus supplement is available for free by visiting EDGAR on the
SEC's website located at www.sec.gov.
Copie of the prospectus supplement and accompanying prospectus may also
be obtained from the offices of Morgan Stanley & Co. LLC, 180 Varick
Street, 2nd Floor, New York, New York 10014, Attn: Prospectus
Department, by calling toll-free (866) 718 1649 or by email at email@example.com,
or from the offices of J.P. Morgan Securities LLC via Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by
calling toll-free (866) 803-9204.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products
for patients with life-threatening rare diseases and unmet medical need.
Synageva has several protein therapeutics in its pipeline. The company
has assembled a team with a proven record of bringing orphan therapies
This news release and oral statements made from time to time by Synageva
representatives in respect of the same subject matter may contain
"forward-looking statements" under the provisions of the Private
Securities Litigation Reform Act of 1995. Such statements can be
identified by introductory words such as "expects," "plans," "intends,"
"believes," "will," "estimates," "forecasts," "projects," or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Many factors may cause actual results to
differ materially from forward-looking statements, including inaccurate
assumptions and a broad variety of risks and uncertainties, some of
which are known, including those identified under the heading "Risk
Factors" in the Company's prospectus supplement filed with the
Securities and Exchange Commission (the "SEC") on January 3, 2013 and
other filings the Company periodically makes with the SEC, and others of
which are not. No forward-looking statement is a guarantee of future
results or events, and one should avoid placing undue reliance on such
statements. Synageva undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
"Dedicated to Rare Diseases®" is a registered trademark and "Synageva
BioPharma™" is a trademark of Synageva BioPharma Corp.
[ Back To NFVZone's Homepage ]